Microbial Influences on Amyotrophic Lateral Sclerosis: The Gut–Brain Axis and Therapeutic Potential of Microbiota Modulation
Sclerosis,
Journal Year:
2025,
Volume and Issue:
3(1), P. 8 - 8
Published: March 5, 2025
Background/Objectives:
Amyotrophic
lateral
sclerosis
(ALS)
is
a
neurodegenerative
disorder
characterized
by
the
progressive
degeneration
of
motor
neurons.
The
gut
microbiota,
community
microorganisms
in
digestive
tract,
has
recently
been
implicated
ALS
pathogenesis
through
its
influence
on
neuroinflammation
and
metabolic
pathways.
This
review
explores
potential
role
microbiota
metabolites
progression
investigates
therapeutic
approaches
targeting
microbiota.
Methods:
A
comprehensive
current
literature
was
conducted
to
assess
relationship
between
composition,
microbial
metabolites,
patients.
We
searched
for
published
reports
ALS,
emphasizing
complex
interplay
dysbiosis,
neuroinflammation,
systemic
metabolism.
Special
emphasis
placed
studies
exploring
short-chain
fatty
acids
(SCFAs),
bacterial
amyloids
(curli-like
factors),
neurotoxins
such
as
β-methylamino-L-alanine
(BMAA).
liver–gut
axis
evaluated
well.
changes
would
sustain
rationale
strategies
probiotics,
prebiotics,
fecal
transplantation
(FMT),
dietary
interventions.
Results:
patients
exhibit
reduced
SCFA-producing
bacteria
an
increase
potentially
pathogenic
genera.
Of
note,
different
do
not
agree
common
patterns
being
linked
supporting
need
further,
more
extensive
studies.
Dysbiosis
sometimes
correlates
with
inflammation
disrupted
liver
function,
amplifying
neuroinflammatory
responses.
Key
including
SCFAs,
amyloids,
BMAA,
may
exacerbate
neuron
promoting
protein
misfolding,
oxidative
stress,
neuroinflammation.
Emerging
strategies,
probiotics
FMT,
show
restoring
balance,
although
clinical
data
remain
limited.
Conclusions:
could
modulate
metabolism
ALS.
Microbiota-targeted
therapies,
interventions,
represent
promising
avenues
mitigating
disease
progression.
Further
research
required
validate
these
interventions
large-scale,
longitudinal
develop
personalized
microbiota-based
treatments
tailored
individual
phenotypes.
Language: Английский
The microbial metabolite trimethylamine N-oxide and the kidney diseases
Jian Su,
No information about this author
Xiangqi Wu,
No information about this author
Qi Wang
No information about this author
et al.
Frontiers in Cellular and Infection Microbiology,
Journal Year:
2025,
Volume and Issue:
15
Published: March 11, 2025
Trimethylamine
N-oxide
(TMAO),
a
metabolite,
is
co-metabolite
produced
by
both
gut
microbiota
and
livers,
originating
from
foods
rich
in
choline
or
carnitine.
Emerging
evidence
suggests
that
TMAO
may
play
role
the
pathogenesis
of
various
kidney
diseases,
including
acute
injury
chronic
disease.
Research
has
demonstrated
heightened
levels
are
correlated
with
likelihood
disease
advancement
cardiovascular
incidents
among
individuals
Furthermore,
been
observed
to
stimulate
inflammation,
oxidative
stress,
fibrosis
animal
models
Mechanistically,
contribute
inhibiting
autophagy,
activating
NLRP3
inflammasome,
inducing
mitochondrial
dysfunction.
Therefore,
targeting
represent
promising
therapeutic
strategy
for
treatment
diseases.
Future
studies
needed
further
investigate
develop
TMAO-targeted
therapies
prevention
Language: Английский
Association between serum alpha-1-acid glycoprotein (AGP) levels and depression: The mediation effect of triglyceride-glucose (TyG) index
Journal of Affective Disorders,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 1, 2025
Language: Английский
Molecular Mechanisms and Emerging Precision Therapeutics in the Gut Microbiota-Cardiovascular Axis
Jhon Alexander Ponce Alencastro,
No information about this author
Diego Lucero,
No information about this author
Ricardo Pérez-Solís
No information about this author
et al.
Cureus,
Journal Year:
2025,
Volume and Issue:
unknown
Published: April 26, 2025
Language: Английский
Association Between Lifestyle Patterns and Abdominal Obesity with Biochemical and Inflammatory Biomarkers in Adolescents with Down Syndrome: The UP&DOWN Study
Nutrients,
Journal Year:
2024,
Volume and Issue:
16(22), P. 3884 - 3884
Published: Nov. 14, 2024
The
main
objective
of
this
study
was
to
examine
the
association
between
lifestyle
patterns
(physical
activity,
screen
and
sleep
time
diet)
abdominal
obesity,
endocrine,
metabolic,
immunological
biomarkers
in
adolescents
with
Down
syndrome
(DS).
Language: Английский
The Microbiota–Gut–Brain Axis: Key Mechanisms Driving Glymphopathy and Cerebral Small Vessel Disease
Life,
Journal Year:
2024,
Volume and Issue:
15(1), P. 3 - 3
Published: Dec. 24, 2024
The
human
microbiota
constitute
a
very
complex
ecosystem
of
microorganisms
inhabiting
both
the
inside
and
outside
our
bodies,
in
which
health
maintenance
disease
modification
are
main
regulatory
features.
recent
explosion
microbiome
research
has
begun
to
detail
its
important
role
neurological
health,
particularly
concerning
cerebral
small
vessel
(CSVD),
disorder
associated
with
cognitive
decline
vascular
dementia.
This
narrative
review
represents
state-of-the-art
knowledge
intimate,
interplay
between
brain
through
gut-brain
axis
(GBA)
emerging
glymphatic
system
dysfunction
(glymphopathy)
circulating
cell-derived
microparticles
(MPs)
as
mediators
these
interactions.
We
discuss
how
microbial
dysbiosis
promotes
neuroinflammation,
dysfunction,
impaired
waste
clearance
brain,
critical
factors
pathogenesis
CSVD.
Further,
we
lifestyle
that
shape
composition
functionality
microbiota,
focusing
on
sleep
modifiable
risk
factor
disorders.
presents
from
neuroscientific
perspective
establish
future
therapeutic
avenues
targeting
improve
reduce
burden
Language: Английский